Abbott Laboratories ROA 2006-2018 | ABT
Current and historical return on assets (ROA) values for Abbott Laboratories (ABT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Abbott Laboratories ROA for the three months ending December 31, 2018 was 7.30%.
| Abbott Laboratories ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-12-31 | $2.37B | $0.00B | 4.49% |
| 2018-09-30 | $0.89B | $71.64B | 1.23% |
| 2018-06-30 | $0.93B | $68.42B | 1.29% |
| 2018-03-31 | $0.48B | $70.91B | 0.66% |
| 2017-12-31 | $0.48B | $76.25B | 0.66% |
| 2017-09-30 | $2.10B | $72.25B | 3.15% |
| 2017-06-30 | $1.17B | $71.15B | 2.00% |
| 2017-03-31 | $1.50B | $70.89B | 2.96% |
| 2016-12-31 | $1.40B | $52.67B | 3.26% |
| 2016-09-30 | $1.37B | $39.50B | 3.42% |
| 2016-06-30 | $2.28B | $39.83B | 5.61% |
| 2016-03-31 | $2.45B | $39.64B | 5.87% |
| 2015-12-31 | $4.42B | $41.25B | 10.40% |
| 2015-09-30 | $4.56B | $41.73B | 10.72% |
| 2015-06-30 | $4.52B | $44.13B | 10.57% |
| 2015-03-31 | $4.20B | $43.10B | 9.99% |
| 2014-12-31 | $2.28B | $41.21B | 5.48% |
| 2014-09-30 | $1.97B | $42.51B | 4.67% |
| 2014-06-30 | $2.40B | $41.48B | 5.63% |
| 2014-03-31 | $2.41B | $41.66B | 5.61% |
| 2013-12-31 | $2.58B | $42.95B | 5.97% |
| 2013-09-30 | $3.04B | $44.13B | 6.17% |
| 2013-06-30 | $4.02B | $42.90B | 7.43% |
| 2013-03-31 | $5.27B | $42.69B | 8.96% |
| 2012-12-31 | $5.96B | $67.24B | 9.36% |
| 2012-09-30 | $6.53B | $63.26B | 10.54% |
| 2012-06-30 | $4.89B | $61.86B | 8.01% |
| 2012-03-31 | $5.11B | $62.42B | 8.36% |
| 2011-12-31 | $4.73B | $60.28B | 7.77% |
| 2011-09-30 | $4.55B | $59.63B | 7.47% |
| 2011-06-30 | $5.14B | $62.00B | 8.51% |
| 2011-03-31 | $4.49B | $61.65B | 7.71% |
| 2010-12-31 | $4.63B | $60.57B | 8.24% |
| 2010-09-30 | $4.73B | $57.37B | 8.72% |
| 2010-06-30 | $5.31B | $53.38B | 10.16% |
| 2010-03-31 | $5.31B | $53.36B | 10.44% |
| 2009-12-31 | $5.75B | $52.58B | 11.76% |
| 2009-09-30 | $5.74B | $49.85B | 12.39% |
| 2009-06-30 | $5.35B | $47.63B | 12.07% |
| 2009-03-31 | $5.38B | $45.44B | 12.39% |
| 2008-12-31 | $4.88B | $42.42B | 11.52% |
| 2008-09-30 | $4.55B | $41.75B | 10.91% |
| 2008-06-30 | $4.18B | $44.07B | 10.28% |
| 2008-03-31 | $3.85B | $41.18B | 9.89% |
| 2007-12-31 | $3.61B | $39.71B | 9.57% |
| 2007-09-30 | $1.93B | $37.62B | 5.24% |
| 2007-06-30 | $1.93B | $37.15B | 5.39% |
| 2007-03-31 | $1.55B | $36.29B | 4.43% |
| 2006-12-31 | $1.72B | $36.18B | 5.20% |
| 2006-09-30 | $3.17B | $33.30B | 10.14% |
| 2006-06-30 | $3.13B | $34.06B | 10.40% |
| 2006-03-31 | $3.40B | $28.53B | 11.89% |
| 2005-12-31 | $3.37B | $29.14B | 11.76% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $132.673B | $30.578B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $124.635B | 18.20 |
| Stryker (SYK) | United States | $69.927B | 25.67 |
| Boston Scientific (BSX) | United States | $55.591B | 27.10 |
| Baxter (BAX) | United States | $39.448B | 24.31 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.289B | 16.23 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.755B | 0.00 |
| ResMed (RMD) | United States | $14.297B | 27.11 |
| Canopy Growth (CGC) | Canada | $10.742B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.172B | 52.25 |
| Aurora Cannabis (ACB) | Canada | $7.060B | 50.50 |
| Hill-Rom Holdings (HRC) | United States | $6.958B | 21.52 |
| Perrigo (PRGO) | Ireland | $6.649B | 10.09 |
| ICU Medical (ICUI) | United States | $5.184B | 28.88 |
| Insulet (PODD) | United States | $5.071B | 0.00 |
| Haemonetics (HAE) | United States | $4.540B | 40.28 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.400B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.380B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.329B | 0.00 |
| Neogen (NEOG) | United States | $3.267B | 50.18 |
| NuVasive (NUVA) | United States | $2.850B | 24.96 |
| Quidel (QDEL) | United States | $2.761B | 24.91 |
| National Vision Holdings (EYE) | United States | $2.637B | 51.01 |
| Aphria (APHA) | $2.539B | 112.78 | |
| NxStage Medical (NXTM) | United States | $2.000B | 0.00 |
| AtriCure (ATRC) | United States | $1.274B | 0.00 |
| HEXO (HEXO) | $1.242B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.240B | 890.25 |
| Phibro Animal Health (PAHC) | United States | $1.220B | 17.53 |
| VAREX IMAGING (VREX) | United States | $1.212B | 23.73 |
| MacroGenics (MGNX) | United States | $0.939B | 0.00 |
| Cerus (CERS) | United States | $0.904B | 0.00 |
| PetIQ (PETQ) | United States | $0.867B | 22.47 |
| Lantheus Holdings (LNTH) | United States | $0.847B | 22.95 |
| Surmodics (SRDX) | United States | $0.785B | 114.20 |
| Meridian Bioscience (VIVO) | United States | $0.733B | 21.85 |
| NanoString Technologies (NSTG) | United States | $0.721B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.720B | 31.76 |
| Omeros (OMER) | United States | $0.719B | 0.00 |
| Evolus (EOLS) | United States | $0.705B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.647B | 20.75 |
| LeMaitre Vascular (LMAT) | United States | $0.603B | 28.76 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.426B | 0.00 |
| Owens & Minor (OMI) | United States | $0.408B | 5.65 |
| TG Therapeutics (TGTX) | United States | $0.398B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.339B | 21.99 |
| BioLife Solutions (BLFS) | United States | $0.329B | 445.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.294B | 0.00 |
| Vapotherm (VAPO) | United States | $0.288B | 0.00 |
| Bovie Medical (APYX) | United States | $0.282B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.262B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.256B | 0.00 |
| Zynex (ZYXI) | United States | $0.174B | 16.84 |
| Fonar (FONR) | United States | $0.144B | 7.70 |
| Surface Oncology (SURF) | United States | $0.140B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.112B | 0.00 |
| Chimerix (CMRX) | United States | $0.100B | 0.00 |
| United-Guardian (UG) | United States | $0.090B | 18.77 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.078B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 18.20 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.057B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 14.14 |
